Works about HER2 positive breast cancer

Results: 1007

HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer—A Multicenter Retrospective Cohort Study.

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 13, p. 4431, doi. 10.3390/jcm14134431

By:

Seyyar, Mustafa;
Şancı, Pervin Can;
Köşeci, Tolga;
Karakayalı, Anıl;
Akdağ, Mutianur Özkorkmaz;
Temi, Yasemin Bakkal;
Uygun, Kazım;
Kefeli, Umut;
Mete, Burak;
Çabuk, Devrim

Publication type:

Article

Highlights of 2024. Broadening anti‐cancer immunotherapy modalities with antibody–drug conjugates: emerging insights from clinical studies.

Published in:

Immunology & Cell Biology, 2025, v. 103, n. 6, p. 530, doi. 10.1111/imcb.70017

By:

Jose, Jiya;
Hooper, John D;
Souza‐Fonseca‐Guimaraes, Fernando

Publication type:

Article

Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer.

Published in:

Journal of Experimental & Clinical Cancer Research (17569966), 2025, v. 44, n. 1, p. 1, doi. 10.1186/s13046-025-03454-z

By:

Huang, Juan;
Zhu, Yongwei;
Zeng, Wenjing;
Zhang, Yulong;
Xia, Weizhi;
Xia, Fan;
Liu, Liyu;
Wang, Kuansong;
Guan, Yidi;
Shen, Taohong;
Jiang, Bingjian;
Sun, Lunquan;
Cao, Ayong;
Wang, Shouman;
Li, Zhi

Publication type:

Article

Structural insights and predictive modelling of a novel anti-HER2 scFv and Leptulipin: a newly designed immunotoxin protein for HER2 positive cancers.

Published in:

Toxicology Research, 2025, v. 14, n. 3, p. 1, doi. 10.1093/toxres/tfaf060

By:

Kalsoom, Maria;
Rehman, Hafiz Muzzammel;
Al-Qassab, Yasamin;
Rehman, Hafiz Muhammad;
Syed, Rabbani;
Ahmed, Nadeem;
Wu, Yurong;
Al-Qahtani, Ahmed A;
Nadeem, Tariq;
Bashir, Hamid

Publication type:

Article

A computational study of cardiac glycosides from Vernonia amygdalina as PI3K inhibitors for targeting HER2 positive breast cancer.

Published in:

Journal of Computer-Aided Molecular Design, 2025, v. 39, n. 1, p. 1, doi. 10.1007/s10822-025-00621-4

By:

Tafrihani, Ahmad Syauqy;
Hanif, Naufa;
Yoga, I Made Bayu Kresna;
Irmasari, Irmasari;
Fakih, Taufik Muhammad;
Novitasari, Dhania;
Hasibuan, Poppy Anjelisa Zaitun;
Satria, Denny;
Huda, Fathul;
Muchtaridi, Muchtaridi;
Hermawan, Adam

Publication type:

Article

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial Open Access.

Published in:

JNCI Cancer Spectrum, 2025, v. 9, n. 3, p. 1, doi. 10.1093/jncics/pkaf032

By:

Bandos, Hanna;
Kim, Sungjin;
Henry, N Lynn;
Hays, Ron D;
Calsavara, Vinicius F;
Luu, Michael;
Gresham, Gillian;
Lu, Kit Y;
Irvin, William J;
Suga, J Marie;
Siddique, Shahzad;
Cecchini, Reena S;
Rogatko, André;
Yothers, Greg;
Tighiouart, Mourad;
Ganz, Patricia A

Publication type:

Article

Plasma IFN-γ may predict pyrotinib efficacy in patients with HER2-positive advanced breast cancer.

Published in:

Biomedical Reports, 2025, v. 23, n. 2, p. N.PAG, doi. 10.3892/br.2025.2004

By:

Jia, Jinghao;
Wang, Jing;
Yao, Xuemin;
Liu, Jingjing

Publication type:

Article

Clinical TP53 genetic testing is recommended for HER2-positive breast cancer patients aged 35 or younger.

Published in:

NPJ Genomic Medicine, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41525-025-00496-2

By:

Li, Jing;
Chen, Lili;
Chen, Xuhui;
Huang, Meng;
Guo, Wenhui;
Chen, Minyan;
Lin, Yuxiang;
Wang, Yali;
Cai, Weifeng;
Qiu, Yibin;
He, Peng;
Cai, Qindong;
Wang, Chuan;
Fu, Fangmeng

Publication type:

Article

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Published in:

Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-61213-2

By:

Niu, Nan;
Xue, Jinqi;
Chen, Guanglei;
Qiu, Fang;
Xu, Qianshi;
Zheng, Xinyu;
Liu, Chao;
Zhao, Yafei;
Gu, Xi;
Zhao, Yi;
Xu, Hong;
Zhang, Hao;
He, Guijin;
Li, Ke;
Li, Pengfei;
Chen, Xiaoying;
Li, Yong;
Wang, Shuo;
Zhu, Demiao;
Liu, Tong

Publication type:

Article

Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14404-5

By:

Wang, Chaoyang;
Xiao, Dong;
Zhai, Chao

Publication type:

Article

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study.

Published in:

World Journal of Surgical Oncology, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12957-025-03909-9

By:

Wang, Junxiao;
Yu, Yushuai;
Lin, Qisheng;
Wang, Xin

Publication type:

Article

Advances in Bioactive Compounds and Cancer Therapy—Insights from the Special Issue "Bioactive Compounds in Cancers".

Published in:

International Journal of Molecular Sciences, 2025, v. 26, n. 12, p. 5632, doi. 10.3390/ijms26125632

By:

Bousbaa, Hassan;
Cidade, Honorina;
Silva, Patrícia M. A.

Publication type:

Article

89 Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging.

Published in:

Pharmaceutics, 2025, v. 17, n. 6, p. 739, doi. 10.3390/pharmaceutics17060739

By:

Tudoroiu-Cornoiu, Maria-Roxana;
Șerban, Radu Marian;
Cocioabă, Diana;
Niculae, Dragoș Andrei;
Drăgănescu, Doina;
Leonte, Radu;
Ion, Alina Catrinel;
Niculae, Dana

Publication type:

Article

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer.

Published in:

Pharmaceuticals (14248247), 2025, v. 18, n. 6, p. 931, doi. 10.3390/ph18060931

By:

Surmeli, Heves;
Isik, Deniz;
Kinikoglu, Oguzcan;
Altintas, Yunus Emre;
Ozkerim, Ugur;
Oksuz, Sıla;
Basoglu, Tugba;
Odabas, Hatice;
Turan, Nedim

Publication type:

Article

Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer.

Published in:

Biotechnology Letters, 2023, v. 45, n. 3, p. 371, doi. 10.1007/s10529-022-03342-y

By:

Ahmadzadeh, Maryam;
Mohit, Elham

Publication type:

Article

Correction: Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.

Published in:

2025

By:

van der Voort, Anna;
van der Hoogt, Kay J. J.;
Wessels, Ronni;
Schipper, Robert-Jan;
Wesseling, Jelle;
Sonke, Gabe S.;
Mann, Ritse M.

Publication type:

Correction Notice

Imaging evaluation of neoadjuvant breast cancer treatment: where do we stand?

Published in:

2024

By:

Álvarez-Benito, Marina

Publication type:

Editorial

Anti-HER2 therapy response assessment for guiding treatment (de-)escalation in early HER2-positive breast cancer using a novel deep learning radiomics model.

Published in:

European Radiology, 2024, v. 34, n. 8, p. 5477, doi. 10.1007/s00330-024-10609-7

By:

Tong, Yiwei;
Hu, Zhaoyu;
Wang, Haoyu;
Huang, Jiahui;
Zhan, Ying;
Chai, Weimin;
Deng, Yinhui;
Yuan, Ying;
Shen, Kunwei;
Wang, Yuanyuan;
Chen, Xiaosong;
Yu, Jinhua

Publication type:

Article

BRCA1/2突变HER2阳性乳腺癌的临床特征及其对新辅助靶向治疗的反应.

Published in:

Cancer Research on Prevention & Treatment, 2025, v. 52, n. 6, p. 491, doi. 10.3971/j.issn.1000-8578.2025.25.0101

By:

廖兴宇;
刘慧敏;
孙洁;
胡丽;
张娟;
姚璐;
徐晔;
解云涛

Publication type:

Article

Intratumoral and peritumoral ultrasound radiomics analysis for predicting HER2-low expression in HER2-negative breast cancer patients: a retrospective analysis of dual-central study.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02752-4

By:

Wang, Jiajia;
Gu, Yunxin;
Zhan, Yunyun;
Li, Rubing;
Bi, Yu;
Gao, Lan;
Wu, Xiabi;
Shao, Jiaqi;
Chen, Yilin;
Ye, Lei;
Peng, Mei

Publication type:

Article

Unveiling GBE1 as a hypoxia-related prognostic gene with significant impact on immune cell infiltration in HER2-enriched breast cancer.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02826-3

By:

Hasannejad, Farkhonde;
Darzi, Mohammad;
Yasaei, Mehrdad

Publication type:

Article

Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02192-0

By:

Celik Demirbas, Betul;
Kilic Erciyas, Seda;
Sukruoglu Erdogan, Ozge;
Pasin, Ozge;
Yalniz Kayim, Zubeyde;
Özgel, Merve Çiğdem;
Tuncer, Seref Bugra

Publication type:

Article

Non-drug related costs of treatment with pertuzumab and trastuzumab in HER2-positive breast cancer patients in Poland.

Published in:

Oncology in Clinical Practice (2450-1654), 2024, v. 20, n. 3, p. 181, doi. 10.5603/ocp.97426

By:

Seweryn, Michał;
Banaś, Tomasz;
Augustyńska, Joanna;
Leszczyńska, Agnieszka;
Potocki, Paweł M.

Publication type:

Article

Commentary: on Trastuzumab deruxtecan in the treatment of adult patients with HER-positive breast cancer.

Published in:

Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 5, p. 382, doi. 10.5603/ocp.97613

By:

Krzakowski, Maciej

Publication type:

Article

Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer.

Published in:

Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 5, p. 377, doi. 10.5603/ocp.97612

By:

Kufel-Grabowska, Joanna

Publication type:

Article

Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience.

Published in:

Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 4, p. 235, doi. 10.5603/OCP.2023.0020

By:

Duc Thanh Le;
Tu Anh Do;
Lap Thanh Bui;
Kien Hung Do;
Chu Van Nguyen

Publication type:

Article

The role of anthracycline and pertuzumab in preoperative treatment of HER2-positive breast cancer.

Published in:

Oncology in Clinical Practice (2450-1654), 2023, v. 19, n. 1, p. 50, doi. 10.5603/OCP.2022.0012

By:

Dębska-Szmich, Sylwia;
Potemski, Piotr

Publication type:

Article

Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.

Published in:

European Radiology Experimental, 2023, v. 7, n. 1, p. 1, doi. 10.1186/s41747-023-00338-9

By:

Cheng, Sainan;
Wang, Jianwei;
Wang, Yawen;
Qi, Linlin;
Li, Fenglan;
Liu, Jianing;
Chen, Jiaqi;
Fan, Yang;
Xie, Lizhi

Publication type:

Article

Systematic Review of the Antitumor Activities and Mechanisms of Scorpion Venom on Human Breast Cancer Cells Lines (In Vitro Study).

Published in:

Journal of Clinical Medicine, 2025, v. 14, n. 9, p. 3181, doi. 10.3390/jcm14093181

By:

Kwon, Na-Yoen;
Sung, Hyun-Kyung;
Park, Jang-Kyung

Publication type:

Article

Computer-Assisted Algorithm for Quantification of Fibrosis by Native Cardiac CT: A Pilot Study.

Published in:

Journal of Clinical Medicine, 2024, v. 13, n. 16, p. 4807, doi. 10.3390/jcm13164807

By:

Gonciar, Diana;
Berciu, Alexandru-George;
Dulf, Eva-Henrietta;
Orzan, Rares Ilie;
Mocan, Teodora;
Danku, Alex Ede;
Lorenzovici, Noemi;
Agoston-Coldea, Lucia

Publication type:

Article

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 21, p. 6708, doi. 10.3390/jcm12216708

By:

de la Brassinne Bonardeaux, Orianne;
Born, Benjamin;
Moonen, Marie;
Lancellotti, Patrizio

Publication type:

Article

PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 15, p. 4882, doi. 10.3390/jcm12154882

By:

McGale, Jeremy;
Khurana, Sakshi;
Huang, Alice;
Roa, Tina;
Yeh, Randy;
Shirini, Dorsa;
Doshi, Parth;
Nakhla, Abanoub;
Bebawy, Maria;
Khalil, David;
Lotfalla, Andrew;
Higgins, Hayley;
Gulati, Amit;
Girard, Antoine;
Bidard, Francois-Clement;
Champion, Laurence;
Duong, Phuong;
Dercle, Laurent;
Seban, Romain-David

Publication type:

Article

History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 10, p. 3391, doi. 10.3390/jcm12103391

By:

Ariga, Shin

Publication type:

Article

Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1278, doi. 10.3390/jcm12041278

By:

Cronin, Michael;
Crowley, Aileen;
Davey, Matthew G.;
Ryan, Peter;
Abdelshafy, Mahmoud;
Elkoumy, Ahmed;
Elzomor, Hesham;
Arsang-Jang, Shahram;
Ganly, Sandra;
Nash, Patrick;
Crowley, James;
Sharif, Faisal;
Simpkin, Andrew;
Lowery, Aoife;
Wijns, William;
Kerin, Michael;
Soliman, Osama

Publication type:

Article

Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 5, p. 1434, doi. 10.3390/jcm11051434

By:

Hung, Chih-Chiang;
Tsai, I-Chen;
Hsu, Chiann-Yi;
Lin, Hsin-Chen

Publication type:

Article

Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 3, p. 847, doi. 10.3390/jcm11030847

By:

Suntheralingam, Sivisan;
Fan, Chun-Po Steve;
Calvillo-Argüelles, Oscar;
Abdel-Qadir, Husam;
Amir, Eitan;
Thavendiranathan, Paaladinesh

Publication type:

Article

Elevated Baseline Serum PD-L1 Level May Predict Poor Outcomes from Breast Cancer in African-American and Hispanic Women.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 2, p. 283, doi. 10.3390/jcm11020283

By:

Wu, Yanyuan;
Dutta, Pranabananda;
Clayton, Sheilah;
McCloud, Amaya;
Vadgama, Jaydutt V.

Publication type:

Article

Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer.

Published in:

2022

By:

Dong, Xinrui;
Dai, Huijuan;
Sun, Aijun;
Yu, Zhenfeng;
Du, Yueyao

Publication type:

journal article

Comprehensive Analysis of the Expression and Prognostic Value of LMAN2 in HER2+ Breast Cancer.

Published in:

2022

By:

Zhang, Di;
Ye, Liping;
Hu, Shuang;
Zhu, Qingqing;
Li, Chenxi;
Zhu, Chengming

Publication type:

journal article

Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy.

Published in:

European Journal of Medical Research, 2025, v. 30, n. 1, p. 1, doi. 10.1186/s40001-024-02188-6

By:

Hu, Yangling;
Li, Meizhi;
Hu, Yalan;
Wang, Mengyi;
Lin, Yingyu;
Mao, Lijuan;
Wang, Chaoyang;
Shui, Yanhong;
Song, Yutong;
Wang, Huan;
Ji, Lin;
Che, Xin;
Shao, Nan;
Zhang, Xiaoling

Publication type:

Article

Echocardiographic Assessment of Ventricular Cardiomyopathy in Patients with Breast Cancer under Trastuzumab Chemotherapy.

Published in:

Journal of Cardio-Thoracic Medicine, 2024, v. 12, n. 2, p. 1329, doi. 10.22038/jctm.2024.79819.1458

By:

Khansari, Nakisa;
Shahbazi, Paria;
Homayounfar, Shahram;
Abbasi, Mohammad;
Moradi, Abbas;
Sedighi, Parinaz

Publication type:

Article

Development and evaluation of <sup>89</sup>Zr-trastuzumab for clinical applications.

Published in:

Asia Oceania Journal of Nuclear Medicine & Biology, 2023, v. 11, n. 2, p. 135, doi. 10.22038/AOJNMB.2022.68093.1471

By:

Mohammadpour-Ghazi, Fatemeh;
Yousefnia, Hassan;
Divband, GhasemAli;
Zolghadri, Samaneh;
Alirezapour, Behrouz;
Shakeri, Fatemeh

Publication type:

Article

Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice.

Published in:

Toxicology Research, 2022, v. 11, n. 1, p. 184, doi. 10.1093/toxres/tfab111

By:

Tao, Gabriel;
Dagher, Fatima;
Ghose, Romi

Publication type:

Article

GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-99685-3

By:

Li, Hongyu;
Zhang, Yalin;
Han, Xiao;
Li, Bingyu;
Liu, Dan;
Sun, Gang

Publication type:

Article

Identification of M1 macrophage infiltration-related genes for immunotherapy in Her2-positive breast cancer based on bioinformatics analysis and machine learning.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-96917-4

By:

Wang, Sizhang;
Wang, Xiaoyan;
Xia, Jing;
Mu, Qiang

Publication type:

Article

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.

Published in:

BMC Pharmacology & Toxicology, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s40360-022-00599-x

By:

Nodehi, Reza Safaei;
Kalantari, Behjat;
Raafat, Jahangir;
Ansarinejad, Nafiseh;
Moazed, Vahid;
Mortazavizadeh, Seyed Mohammad Reza;
Hosseinzadeh, Mehran;
Ghaderi, Bayazid;
Jenabian, Arash;
Qadyani, Mojtaba;
Haghighat, Shirin;
Allahyari, Abolghasem;
Mirzania, Mehrzad;
Seghatoleslami, Mohammad;
Payandeh, Mehrdad;
Alikhasi, Afsaneh;
Kafi, Hamidreza;
Shahi, Farhad

Publication type:

Article

Network Pharmacological Analysis Identifies the Curcumin Analog CCA-1.1 Targeting Mitosis Regulatory Process in HER2-Positive Breast Cancer.

Published in:

Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia, 2023, v. 34, n. 1, p. 54

By:

Novitasari, Dhania;
Jenie, Riris Istighfari;
Jun-ya Kato;
Edy Meiyanto

Publication type:

Article

Excellent efficacy of trastuzumab deruxtecan in a patient with HER2-positive advanced breast cancer complicated by pulmonary lymphangitic carcinomatosis: a case report and literature review.

Published in:

2025

By:

Luo, Simin;
Chai, Jie;
Ding, Linxiaoxiao;
Tang, Song

Publication type:

Case Study

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1538881

By:

Tang, Xiting;
Wang, Chengliang;
Li, Yanwei;
Tang, Jing;
Zhang, Guoping;
Chen, Li

Publication type:

Article

A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients.

Published in:

Frontiers in Pharmacology, 2024, p. 1, doi. 10.3389/fphar.2024.1432944

By:

Zhu, Yunfang;
Xu, Yuxiang;
Zhao, Haopeng;
Qie, Hongxin;
Gao, Xiaonan;
Gao, Jinglin;
Feng, Zhangying;
Bai, Jing;
Feng, Rui;
Wang, Mingxia

Publication type:

Article